BYDUREON PEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BYDUREON PEN (BYDUREON PEN).
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
| Metabolism | Proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) and renal excretion |
| Excretion | Renal excretion of intact exenatide via glomerular filtration and proteolytic degradation; approximately 100% of administered dose eliminated via renal pathways (urine) as intact peptide and metabolites. |
| Half-life | Terminal elimination half-life is 2.4 hours following subcutaneous administration; due to extended-release microspheres, systemic exposure is sustained over 10 weeks with multiple dosing (effective half-life ~2 weeks). |
| Protein binding | 94% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd is approximately 28.3 L (0.4 L/kg for a 70 kg adult); indicates distribution into total body water and some tissue binding. |
| Bioavailability | Subcutaneous: 100% (absolute bioavailability not determined due to lack of IV formulation, but absorption is complete from the injection site; extended-release formulation provides continuous release over weeks). |
| Onset of Action | Subcutaneous: 2 hours (glucose-lowering effect begins); peak effect on postprandial glucose occurs at approximately 2-4 hours after each dose; steady state reached after 6-7 weeks of once-weekly dosing. |
| Duration of Action | Duration of action is approximately 10 weeks due to continuous release from microspheres; clinical effect (HbA1c reduction) persists for 10 weeks after last injection; glucose-lowering effect present throughout dosing interval. |
2 mg subcutaneously once every 7 days (weekly)
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for GFR >=30 mL/min. Not recommended for GFR <30 mL/min or ESRD. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; caution in elderly due to potential for renal impairment and gastrointestinal adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BYDUREON PEN (BYDUREON PEN).
| Breastfeeding | Unknown if excreted in human milk. M/P ratio not determined. Consider benefits of breastfeeding and importance of drug to mother. Caution recommended due to potential adverse effects in nursing infants. |
| Teratogenic Risk | FDA Pregnancy Category C. Animal studies show fetal harm at high doses. First trimester: potential risk of fetal malformations; second and third trimesters: risk of fetal hypoglycemia and growth abnormalities. Use only if benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Personal or family history of medullary thyroid carcinoma (MTC)","Multiple endocrine neoplasia syndrome type 2 (MEN 2)","Known hypersensitivity to exenatide or any product components"]
| Precautions | ["Risk of thyroid C-cell tumors (medullary thyroid carcinoma) observed in animal studies","Acute pancreatitis","Hypoglycemia when used with insulin secretagogues or insulin","Renal impairment","Gastrointestinal adverse reactions","Hypersensitivity reactions"] |
| Food/Dietary | No specific food interactions. However, BYDUREON PEN delays gastric emptying, which may increase the risk of nausea and vomiting when consuming large, high-fat meals. Advise patients to eat smaller, low-fat meals during initiation. Avoid alcohol, which can increase hypoglycemia risk, especially if used with sulfonylureas or insulin. |
Loading safety data…
| Monitor maternal blood glucose and HbA1c. Fetal ultrasound for growth and development. Monitor for signs of hypoglycemia in neonate. |
| Fertility Effects | No human data on fertility. Animal studies show no impairment of fertility at doses up to 6 times MRHD. |
| Clinical Pearls | BYDUREON PEN (exenatide extended-release) is a once-weekly GLP-1 receptor agonist. Administer subcutaneously in the abdomen, thigh, or deltoid area on the same day each week. Do not co-administer with short-acting exenatide. Monitor renal function; avoid in severe renal impairment (CrCl <30 mL/min). Initiate 2 weeks after discontinuing short-acting exenatide, if applicable. Reconfigure suspension immediately prior to injection; if not used right away, store at room temperature and use within 4 weeks. Caution in patients with history of pancreatitis, gastroparesis, or personal/family history of medullary thyroid carcinoma. Consider dose adjustments if adding a sulfonylurea to reduce hypoglycemia risk. |
| Patient Advice | Inject BYDUREON PEN once every 7 days on the same day each week; you may change the injection day as long as at least 3 days have passed since the last dose. · Store unused pens in the refrigerator at 36°F to 46°F (2°C to 8°C); after first use, keep at room temperature not exceeding 77°F (25°C) and use within 4 weeks. · Before injection, tap the pen to re-suspend the white powder; inject right away if not shaken vigorously; if delayed, use within 4 weeks. · Inject into the skin of the abdomen, thigh, or upper arm; rotate injection sites to prevent lipodystrophy. · Do not share pens even if the needle is changed to avoid infection transmission. · Stop injecting and contact your doctor if you experience severe abdominal pain that may radiate to the back, which could be a sign of pancreatitis. · BYDUREON PEN can cause nausea, vomiting, or diarrhea, especially when starting; these usually improve over time. · If you miss a dose, inject as soon as you remember if it is within 3 days of the missed dose; if more than 3 days, skip that dose and resume your regular schedule next week. |